VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).
暂无分享,去创建一个
Jiayan Huang | G. Ying | M. Maguire | Daniel F. Martin | S. Hagstrom | G. Pauer | Gwen M. Sturgill-Short | G. Ying
[1] S. Harding,et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study. , 2013, Ophthalmology.
[2] M. Nardi,et al. VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration. , 2013, Pharmacogenomics.
[3] Ivana K. Kim,et al. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). , 2013, Ophthalmology.
[4] L. Schmetterer,et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration , 2013, British Journal of Ophthalmology.
[5] E. Makalic,et al. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. , 2013, Ophthalmology.
[6] E. Chew,et al. Genetic studies of age-related macular degeneration: lessons, challenges, and opportunities for disease management. , 2012, Ophthalmology.
[7] Christian Simader,et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. , 2012, Ophthalmology.
[8] L. Canani,et al. The C allele of -634G/C polymorphism in the VEGFA gene is associated with increased VEGFA gene expression in human retinal tissue. , 2012, Investigative ophthalmology & visual science.
[9] J. Jonas,et al. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration. , 2012, Ophthalmology.
[10] Ebenezer Daniel,et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. , 2012, Ophthalmology.
[11] M. Nardi,et al. The rs2071559 AA VEGFR-2 Genotype Frequency Is Significantly Lower in Neovascular Age-Related Macular Degeneration Patients , 2012, TheScientificWorldJournal.
[12] M. Nardi,et al. Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. , 2012, Pharmacogenomics.
[13] G. Ying,et al. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: 2-Year Results: Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group‡* , 2012 .
[14] Usha Chakravarthy,et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. , 2012, Ophthalmology.
[15] G. Ying,et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.
[16] Zhenping Huang,et al. Pooled-analysis of the associations between three polymorphisms in the VEGF gene and age-related macular degeneration , 2012, Molecular Biology Reports.
[17] P. A. Pereira,et al. Homozygosity for the +674C>T polymorphism on VEGF gene is associated with age-related macular degeneration in a Brazilian cohort , 2012, Graefe's Archive for Clinical and Experimental Ophthalmology.
[18] A. Tsujikawa,et al. VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration , 2011, Japanese Journal of Ophthalmology.
[19] W. Berger,et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. , 2011, Investigative ophthalmology & visual science.
[20] Glenn J Jaffe,et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.
[21] M. McKibbin,et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration , 2011, British Journal of Ophthalmology.
[22] Giovanni Sato,et al. Association of age-related macular degeneration with polymorphisms in vascular endothelial growth factor and its receptor. , 2010, Ophthalmology.
[23] K. Horie-Inoue,et al. CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration , 2010, Journal of ocular biology, diseases, and informatics.
[24] P. Tommila,et al. Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. , 2010, Ophthalmology.
[25] Aaron Y. Lee,et al. Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration , 2009, Molecular vision.
[26] J. Błasiak,et al. Association between vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in a Polish population. , 2009, Experimental and molecular pathology.
[27] A. Hofman,et al. Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration: the Rotterdam Study. , 2008, Ophthalmology.
[28] Steven J. Harper,et al. VEGF-A splicing: the key to anti-angiogenic therapeutics? , 2008, Nature Reviews Cancer.
[29] F. Tsai,et al. Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration. , 2008, American journal of ophthalmology.
[30] R. Guymer,et al. A tag-single nucleotide polymorphisms approach to the vascular endothelial growth factor-A gene in age-related macular degeneration. , 2007, Molecular vision.
[31] R. Danesi,et al. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. , 2007, Pharmacogenomics.
[32] A. Augustin,et al. Emerging drugs for age-related macular degeneration , 2006, Expert opinion on emerging drugs.
[33] Philip J Rosenfeld,et al. Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[34] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[35] J. Escardo,et al. VEGF polymorphisms are associated with neovascular age-related macular degeneration. , 2006, Human molecular genetics.
[36] Chia-Hung Liu,et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization , 2006, Nucleic Acids Res..
[37] J. Duker,et al. Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography. , 2006, Archives of ophthalmology.
[38] Peter K. Kaiser,et al. ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006 .
[39] J. Gilbert,et al. Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6. , 2006, Investigative ophthalmology & visual science.
[40] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[41] Chris A Johnson,et al. A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. , 2003, American journal of ophthalmology.
[42] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .